Controversial guidelines in early diagnosis of prostate cancer;Recomendaciones divergentes en el diagnostico precoz del cancer de prostata

Medicina

Volumn 63, Issue 1, 2003, Pages 77-81

  Casal, Enrique R ^a   Majdalani, Maria P ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Clinical practice guidelines; Prevention and control; Prostatic neoplasm

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CLINICAL PRACTICE; DISEASE ASSOCIATION; EARLY DIAGNOSIS; HIGH RISK POPULATION; HUMAN; MALE; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MORBIDITY; PHYSICIAN; PRACTICE GUIDELINE; PROBABILITY; PROSTATE CANCER; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; VALIDATION PROCESS; DECISION MAKING; DOCTOR PATIENT RELATION; PATIENT PARTICIPATION; PROSTATE TUMOR; REVIEW; RISK;

DECISION MAKING; HUMANS; MALE; PATIENT PARTICIPATION; PHYSICIAN-PATIENT RELATIONS; PRACTICE GUIDELINES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK;

EID: 0037639730     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Matos EL, Parkin DM, Loria DI, Vilensky M. Geographical patterns of cancer mortality in Argentina. Int J Epidem 1990. 19: 860-70.
2. Food and Drug Administration. FDA approves test for prostate cancer. 1994. Available from: URL: http://www.fda.gov/bbs/topics/answers/ans00598.html
3. Gohogan JK, Prorock PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol 1994; 152: 1905-9.
4. Barry MJ. Is there an easier way to determine whether early detection of prostate cancer reduces mortality? J Gen Intern Med 1997; 12: 657-8.
5. Soldano E. Próstata: de la nuez de Adán a la manzana de la discordia. La Nación. Sección 6. Salud. Pag. 4, (col. 1) 11 de enero de 1995.
6. American Urological Association: Executive Committee Report. Baltimore, American Urological Association, 1992.
7. American Cancer Society: Cancer Detection Guidelines. Prostate. URL: http://www.cancer.org/ Internet Site, American Cancer Society, 2001.
8. Feightner JW. Screening for prostate cancer. In: Canadian Task Force on the periodic health examination. Canadian Guide to Clinical Preventive Health Care. Ottawa: Health Canada, 1994; 812-23.
9. Guide to Clinical Preventive Services . 2nd edition. Report of the U.S. Preventive Services Task Force. Screening for prostate cancer. International Medical Publishing. 1996, 119-34.
10. Adam HO, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet 1994; 343: 958.
11. Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part I: Prior Probability and Effectiveness of Tests. Ann Intern Med. 1997; 126: 394-406.
12. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. Ann Intern Med. 1997; 126: 468-79.
13. Clinical Guideline: Part III. Screening for prostate cancer. American College of Physicians. Ann Intern Med. 1997; 126: 480-4.
14. Fletcher RH, Fletcher SW, Wagner EH. Prevention. Clinical Epidemiology. The Essentials. 3rd edition. 1996. Williams and Wilkins.
15. Byar DP, Corle DK. VACURG randomized trial of radical prostatectomy for stages I and II prostate cancer. Urology 1981 (4 suppl); 17: 7-11.
16. Labrie F., Candas B., Dupont A, at al. Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83-91.
17. Charatan FB. Prostate cancer screening reduces death. BMJ 1998; 316: 576.
18. Farkas A., Schneider D., Perrotti M., Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer, 1973 to 1996, evidence of the effectiveness of prostate specific antigen screening. Urology 1998; 52: 444-8.
19. Jacobsen SJ, Katusic SK, Bergstralh EJ, at al. Incidence of prostate cancer diagnosis in the eras before and after serum Prostate-Specific Antigen testing. JAMA 1995; 274: 1445-9.
20. Mettlin CJ, Murphy GP. Why is the prostate cancer death rate declining in the United States? Cancer 1998. 82: 249-51.
21. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate cancer mortality in England and Wales and the USA. Lancet 2000; 355: 1788-89.
22. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-80.
23. Sackett D, Haynes B, Tugwell P, Guyatt G. Clinical Epidemiology. A basic science for clinical medicine. Early diagnosis. Lippincot Williams & Wilkins Publications. 2nd Edition 1991, p139-55.
24. Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N, Newman TB. Research using existing data. Designing clinical research. Second edition Philadelphia: Lippincott Williams & Wilkins, 2001.
25. Fowler FJ, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy: The National Medicare experience, 1988-1990. Urology 1993; 42: 622-9.
26. D'Amico AV, Whittington R., Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74.
27. Lu-Yao GL, Yao S. Population-based study of long term survival in patients with clinically localized prostate cancer. Lancet 1997; 349: 906-10.
28. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer. The prostate cancer outcome study. JAMA 2000; 283: 354-60.
29. Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002; 346: 1138-44.
30. Paternalism or partnership? Patients have grown up, and there's no going back. BMJ 1999; 319: 719-20.
31. Braddock CH, Fihn SD, Levinson W, Jonsen AR, Pearlman RA. How doctors and patients discuss routine clinical decisions. Informed decision making in the outpatient setting. J Gen Intern Med 1997; 12: 339-45.
32. Flood AB, Wennberg JE, Nease RF Jr., Fowler JR Jr., Ding J, Hynes LM The importance of patient preference in the decision to screen for prostate cancer. J Gen Intern Med 1996; 11: 342-9.
33. Diefenbach PN, Ganz PA, Pawlow AJ, Guthrie D. Screening by the prostate-specific antigen test: What do the patients know ? J Cancer Educ 1996; 11: 39-44.
34. Connelly MT, Ferrari N, Hagen N, Inui TS. Patient-identified needs for hormone replacement therapy counseling: A qualitative study. Ann Intern Med 1999; 131: 265-68.
35. McKinstry B. Do patients wish to be involved in decision making in the consultation? A cross sectional survey with video Vignettes. BMJ 2000; 321: 867-71.
36. Feldman MD, Christensen JF. Behavioral Medicine in Primary Care. A practical guide. Giving Bad News. 1st Edition. New York: Appleton & Lange, 1997.
37. Elwyn G, Edwards A, Gwyn R, Grol R. Towards a feasible model for shared decision making: focus group study with general practice registrars. BMJ. 1999; 319: 753-6.
38. Fowler FJ, McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation therapists for treatment of clinically localized prostate cancer. JAMA 2000; 283: 3217-22.